Atezolizumab plus bevacizumab for metastatic kidney cancer patients with disease progression on atezolizumab or sunitinib

A study published in European Urology this month looks at the use of immunotherapy combined with a vascular endothelial growth factor (VEGF) inhibitor as second-line treatment for metastatic clear cell renal cell carcinoma (RCC). The study investigates the safety and effectiveness of a combination of atezolizumab (immunotherapy) with bevacizumab (VEGF inhibitor) in the second line after […]

read more

Association of immune-related adverse events and outcomes in kidney cancer

Previous studies have shown that cancer patients who experience immune-related side effects (immune-related adverse events) when treated with immunotherapy may have a better response to treatment. This study looks at this effect in patients with metastatic renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (immunotherapy). In the study, 43 patients with metastatic RCC were […]

read more

Anti-cancer vaccine ilixadencel plus sunitinib show promise for untreated metastatic kidney cancer

A phase 2 clinical trial with a new treatment called ilixadencel in combination with sunitinib has shown to improve overall survival in newly diagnosed patients with metastatic renal cell carcinoma (RCC). People given the combination treatment lived 10 months longer than those on sunitinib alone, suggesting that ilixadencel aids survival in these patients. Ilixadencel is […]

read more

Patients with autoimmune disorders have more immune-related side effects to immunotherapy

A study published in The Oncologist recently shows that patients with pre-existing autoimmune disorders are at an increased risk of developing immune-related side effects when treated with immunotherapy. This is regardless of tumour type, gender and general wellbeing. However, these patients can still be treated with immunotherapy. The study included 751 patients with four different […]

read more

Kidney cancer screening pilot piggybacking on Leeds Lung Health Check

Following a chance finding during a lung health screen, a Leeds man discovered that he had kidney cancer. After being spotted early, the cancer was successfully removed. People taking part in a pioneering lung screening trial in Leeds will now also be checked for kidney cancer following additional funding from Yorkshire Cancer Research. This pilot […]

read more

Longer term outcomes with pembrolizumab plus axitinib combination for advanced kidney cancer

This Practice Update interview with Dr Monty Pal from City of Hope Hospital, Duarte, USA and Dr Jun Gong from Cidars-Sinai Medical Centre, Los Angeles, USA reports further follow-up data from the KEYNOTE-426 clinical trial. KEYNOTE-426 is a phase 3 trial looking at the effectiveness of a combination of axitinib and pembrolizumab compared to sunitinib […]

read more

HIF-2α inhibitor belzutifan to be fast-tracked for approval for VHL kidney cancer

Kidney cancers frequently have mutations in a gene called the von Hippel-Lindau (VHL) gene, resulting in high levels of a protein called hypoxia-inducible factor, or HIF-2α. This results in a number of changes in the cancer cells and their surrounding environment that favour tumour growth. The novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), blocks […]

read more

Nivolumab/cabozantinib combination recommended for EMA approval for first-line kidney cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of the nivolumab plus cabozantinib combination for the first-line treatment of people with advanced renal cell carcinoma (RCC). The European Commission will now review the CHMP recommendation and make a final decision in the next few months […]

read more

ASCO GU 2021: Outcomes of first-line immunotherapy combinations in metastatic kidney cancer

Combinations of immunotherapy drugs nivolumab plus ipilimumab and immunotherapy/vascular endothelial growth factor (VEGF) inhibitors are widely used for the treatment of metastatic renal cell carcinoma (RCC). However, limited information is available to compare the outcomes from different combinations. At the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) over the weekend, data […]

read more

ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer

Results from the phase 3 CLEAR study, presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium over the weekend, showed that lenvatinib used in combination with either pembrolizumab or everolimus resulted in improved survival and tumour shrinkage compared to sunitinib when used as a first-line treatment for patients with advanced renal cell […]

read more
Showing 11 to 20 of 998 results
  TOP